Experimental gene therapy for blinding eye disease tested, but study stopped early
NCT ID NCT03328130
First seen Jan 11, 2026 · Last updated May 24, 2026 · Updated 24 times
Summary
This study tested a gene therapy called HORA-PDE6B for people with retinitis pigmentosa caused by a specific genetic defect. The treatment was injected under the retina in one eye to try to improve vision. The study was terminated early, and it is unclear if the therapy was effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Clinique Ophtalmologique, CHU de Nantes
Nantes, 44093, France
Conditions
Explore the condition pages connected to this study.